Imaging Specialists and Pfizer Join Forces for AI-Driven Cardiac Amyloidosis Assessments

Ultromics and Pfizer Partner to Advance AI Detection of Cardiac Amyloidosis

Ultromics, a U.K.-based healthcare company specializing in artificial intelligence (AI) to improve echocardiography evaluations, has announced a new partnership with pharmaceutical giant Pfizer. The collaboration aims to further develop Ultromics’ AI offering for the detection of cardiac amyloidosis, a serious heart condition.